2017
CDK4/6 inhibition triggers anti-tumour immunity
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ. CDK4/6 inhibition triggers anti-tumour immunity. Nature 2017, 548: 471-475. PMID: 28813415, PMCID: PMC5570667, DOI: 10.1038/nature23465.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigen PresentationBiological MimicryBreast NeoplasmsCell Cycle CheckpointsCell Line, TumorCell ProliferationCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Disease Models, AnimalFemaleHumansInterferonsMicePhosphorylationProtein Kinase InhibitorsRepressor ProteinsRNA, Double-StrandedSignal TransductionT-Lymphocytes, RegulatoryTranscriptomeVirusesA randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).
Anders C, Murthy R, Hamilton E, Borges V, Cameron D, Carey L, Müller V, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pivot X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). Journal Of Clinical Oncology 2017, 35: tps1107-tps1107. DOI: 10.1200/jco.2017.35.15_suppl.tps1107.Peer-Reviewed Original ResearchProgression-free survivalMetastatic breast carcinomaBrain metsIndependent data monitoring committeeClinical benefit ratePhase 1b studyDuration of responseIndependent central reviewPrimary study objectiveData monitoring committeeCNS progressionEGFR agentsPo bidBrain metastasesAdult patientsObjective responseOverall survivalCentral reviewStudy treatmentT-DM1CNS therapyTrastuzumab emtansineBenefit rateSelective small molecule inhibitorsBreast carcinoma
2013
Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship
Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Annals Of Oncology 2013, 24: 1434-1443. PMID: 23425944, DOI: 10.1093/annonc/mdt025.Peer-Reviewed Original ResearchConceptsMale breast cancerMale breast cancer patientsBreast cancer patientsRisk factorsBreast cancerSurvivorship issuesCancer patientsEstrogen/androgen ratioMale breast carcinomaEnglish-language literatureEndocrine therapyAndrogen ratioOptimal treatmentBRCA2 mutationsBreast carcinomaPsychosocial sequelaeSystematic reviewPsychosocial impactDiagnostic approachLanguage literaturePatientsCancerAppropriate evaluationDisease biologyMen
2008
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Research And Treatment 2008, 115: 7-12. PMID: 18581232, DOI: 10.1007/s10549-008-0101-7.Peer-Reviewed Original ResearchConceptsStage IV breast cancerOverall survivalBreast cancerStage IV breast carcinomaMedian overall survivalDatabase of patientsAdverse predictorsHer2neu statusUnderwent mastectomySurgery groupLiver metastasesMedian survivalMetastatic diseaseBreast surgeryTherapeutic surgeryBreast carcinomaNS groupRetrospective analysisStaging factorsSurgerySurvivalWomenPatientsMultivariate survivalCancer
2005
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy
Peppercorn J, Herndon J, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E, Group T. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy. Cancer 2005, 104: 1580-1589. PMID: 16118805, DOI: 10.1002/cncr.21363.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBreast NeoplasmsCarmustineChemotherapy, AdjuvantCisplatinCombined Modality TherapyCyclophosphamideDose-Response Relationship, DrugFemaleHumansMiddle AgedNeoplasm StagingQuality of LifeSurvival RateTime FactorsTransplantation, AutologousConceptsQuality of lifeFunctional Living Index-CancerPositive lymph nodesHigh-dose chemotherapySymptom Distress ScaleBreast carcinomaHDC armLymph nodesQOL scoresAutologous bone marrow supportAutologous stem cell supportMcCorkle Symptom Distress ScaleMultiple positive lymph nodesAutologous bone marrow transplantationIntensive adjuvant therapyBone marrow supportHigh-dose cyclophosphamideStem cell supportTotal QOL scoreBone marrow transplantationAdjuvant chemotherapyAdjuvant settingAdjuvant therapyMarrow supportIndex cancer
2004
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal Of Medicine 2004, 351: 971-977. PMID: 15342805, DOI: 10.1056/nejmoa040587.Peer-Reviewed Original ResearchConceptsWomen 70 yearsEarly breast cancerBreast cancerOverall survivalRegional recurrenceDistant metastasisRadiation therapyEstrogen receptor-positive breast carcinomasFrequency of mastectomyClinical stage IPrimary end pointFive-year ratesRate of mastectomyPositive breast cancerYears of ageSignificant differencesAdjuvant therapyAdverse eventsSpecific survivalLocal recurrenceCosmetic resultsOnly significant differenceBreast carcinomaLumpectomyStage I
2003
Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma
Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma. Cancer 2003, 97: 2972-2977. PMID: 12784331, DOI: 10.1002/cncr.11436.Peer-Reviewed Original ResearchConceptsPercent of patientsMetastatic breast carcinomaTrastuzumab-based therapyCentral nervous system metastasesCentral nervous system diseaseNervous system metastasesCNS diseaseNervous system diseasesBreast carcinomaBrain metastasesCNS metastasesLeptomeningeal involvementSystem diseasesDisease sitesMore brain metastasesParenchymal brain metastasesProgressive CNS diseaseFirst-line therapyTime of diagnosisMedian survival periodBlood-brain barrierNew treatment strategiesStable diseaseMetastatic diseasePharmacy records
2001
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E, Group T. Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma. Cancer 2001, 94: 25-36. PMID: 11815957, DOI: 10.1002/cncr.10201.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionMetastatic breast carcinomaClinical congestive heart failureTLC DConventional doxorubicinBreast carcinomaTreatment groupsResponse rateMedian cumulative doxorubicin doseProgesterone receptor-positive patientsWorld Health Organization criteriaCumulative doxorubicin doseOnset of cardiotoxicityPrimary safety endpointReceptor-positive patientsPrimary efficacy endpointRandomized multicenter trialFirst-line therapyFirst-line treatmentPalmar-plantar erythrodysesthesiaCongestive heart failureRelevant prognostic factorsVentricular ejection fractionOverall response rateComparable antitumor activityChanges in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.
Demark-Wahnefried W, Peterson B, Winer E, Marks L, Aziz N, Marcom P, Blackwell K, Rimer B. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. Journal Of Clinical Oncology 2001, 19: 2381-9. PMID: 11331316, DOI: 10.1200/jco.2001.19.9.2381.Peer-Reviewed Original ResearchConceptsBreast cancer patientsCancer patientsPhysical activityWeight gainAdjuvant chemotherapySarcopenic obesityCT groupBody compositionPremenopausal breast cancer patientsOperable breast carcinomaReduced physical activityLeg lean massLean body massSignificant differencesLT patientsPremenopausal womenYears postdiagnosisDietary intakeFat massResistance trainingBreast carcinomaMean changeLean massBody fatChemotherapy
1998
Complications of axillary lymph node dissection for carcinoma of the breast
Warmuth M, Bowen G, Prosnitz L, Chu L, Broadwater G, Peterson B, Leight G, Winer E. Complications of axillary lymph node dissection for carcinoma of the breast. Cancer 1998, 83: 1362-1368. PMID: 9762937, DOI: 10.1002/(sici)1097-0142(19981001)83:7<1362::aid-cncr13>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionLymph node dissectionNode dissectionBreast carcinomaYounger ageGreater body surface areaTreatment factorsAdjuvant tamoxifen therapyEpisodes of infectionHistory of smokingLong-term complicationsMajority of symptomsFrequency of inflammationLong-term symptomsBody surface areaDaily activitiesCross-sectional surveySelf-administered questionnaireArm swellingTamoxifen therapySevere complicationsTerm complicationsYounger patientsPrimary managementRecurrence 2